---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-138249"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:50:06.051620+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atea Q1 2024 net loss $63.2M; Phase 3 COVID trial enrollment complete, results due 2H 2024

## Summary
- Net loss $63.2M ($0.75 per share) vs $35.5M ($0.43) in Q1 2023.
- R&D expense nearly doubled to $57.6M, driven by Phase 3 SUNRISE-3 and Phase 2 HCV trials.
- Cash, equivalents, and marketable securities $541.5M, down $36.6M from year-end 2023.
- Phase 3 COVID trial fully enrolled (2,221 patients in monotherapy cohort); topline results expected 2H 2024.
- Phase 2 HCV lead-in cohort confirmed 98% SVR4; full Phase 2 results expected 2H 2024.

## SEC filing metadata
- accession: 0001193125-24-138249
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312524138249/0001193125-24-138249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312524138249/d798777d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-138249
- JSON: https://secwatch.observer/filing/0001193125-24-138249.json
- Plain text: https://secwatch.observer/filing/0001193125-24-138249.txt

## Key facts
- Earnings Releases
  Atea Pharmaceuticals, Inc. reported financial results for three months ended March 31, 2024.
  - Period: three months ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, Atea Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312524138249/0001193125-24-138249-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.